RxDoctor Payments Data

Boris Khamishon

Neurology · San Diego, CANPI 1104922038

Payments from drug & device makers

$17,516in general payments, 2019–2025

Across 929 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$4K
  • Neurelis, Inc.$2K
  • AbbVie$2K
  • SK Life Science, Inc.$2K
  • Eisai Inc.$1K
  • Biogen$973
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$17,42299%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,516 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$130,721
Medicare patients
268
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)31$140,601
ValtocoDiazepam81$107,352
CopaxoneGlatiramer Acetate19$106,491
UbrelvyUbrogepant110$106,491
FycompaPerampanel74$98,870
BriviactBrivaracetam42$63,931
AptiomEslicarbazepine Acetate33$54,209
VimpatLacosamide30$39,265
RexultiBrexpiprazole26$34,965
QuliptaAtogepant34$34,850
NeuproRotigotine36$34,247
ZonegranZonisamide12$29,393
XcopriCenobamate28$29,063
NayzilamMidazolam25$26,016
BotoxOnabotulinumtoxina19$25,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$2,100$166,861163 claims
UCB, Inc.Briviact, Vimpat, Neupro, Nayzilam$3,987$163,460133 claims
Neurelis, Inc.Valtoco$2,176$107,35281 claims
Teva Pharmaceuticals USA, Inc.Copaxone$227$106,49119 claims
Eisai Inc.Fycompa$1,327$98,87074 claims
Sunovion Pharmaceuticals Inc.Aptiom$537$54,20933 claims
Otsuka America Pharmaceutical, Inc.Rexulti$291$34,96526 claims
SK Life Science, Inc.Xcopri$1,800$29,06328 claims
PfizerNurtec Odt, Dilantin$198$22,75423 claims
Lilly USA, LLCOlanzapine$352$3,178104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →